Similar articles

• Author's reply to Borg et al. Comment on: "EU's new pharmacovigilance legislation: considerations for biosimilars".

  Calvo B. Calvo B. Drug Saf. 2014 Feb;37(2):125-6. doi: 10.1007/s40264-013-0130-y. Drug Saf. 2014. PMID: 24338045 No abstract available.
• EU's new pharmacovigilance legislation: considerations for biosimilars.

  Calvo B, Zuñiga L. Calvo B, et al. Drug Saf. 2014 Jan;37(1):9-18. doi: 10.1007/s40264-013-0121-z. Drug Saf. 2014. PMID: 24190573
• Clinical Trials: Nursing Roles During the Approval Process and Pharmacovigilance of Biosimilars.

  Sugay J. Sugay J. Clin J Oncol Nurs. 2018 Oct 1;22(5):27-32. doi: 10.1188/18.CJON.S1.27-32. Clin J Oncol Nurs. 2018. PMID: 30239528
• Current state of biologic pharmacovigilance in the European Union: improvements are needed.

  Felix T, Jordan JB, Akers C, Patel B, Drago D. Felix T, et al. Expert Opin Drug Saf. 2019 Mar;18(3):231-240. doi: 10.1080/14740338.2019.1577818. Epub 2019 Feb 27. Expert Opin Drug Saf. 2019. PMID: 30714424 Review.
• The Regulation of Biosimilars in Latin America.

  Garcia R, Araujo DV. Garcia R, et al. Curr Rheumatol Rep. 2016 Mar;18(3):16. doi: 10.1007/s11926-016-0564-1. Curr Rheumatol Rep. 2016. PMID: 26951254 Review.